-1366x0.jpg)
The presentation of GENTIS was showcased in the 2024 ASPIRE conference
The conference attracted nearly 1,200 delegates who are experts in assisted reproduction in the region and around the world to attend. At the Conference, GENTIS shared an in-depth topical and scientific research in collaboration with Hanh Phuc International Hospital published in the form of a poster: "Clinical results of embryo transfer based on morphological evaluation combined with non-invasive preimplantation gene testing (NIPGT): A study in Vietnam".
The study evaluated clinical outcomes in two groups: IVF based on embryo morphological assessment alone (control group) and embryo selection group based on embryo morphological assessment combined with niPGT results (ASEM test). The results of the study showed that the proportion of children living in the control group and the study group was 38.6% and 41.1%, respectively. The results of the study also showed that the miscarriage rate in the study group was 0% (no miscarriages were recorded in the study group) and in the control group was 12.9%.
With the results of this initial study, niPGT has the potential to increase the birth rate, especially reduce the miscarriage rate. This is of great significance in helping patients not have to experience the physical and mental trauma of miscarriage. The topic is highly appreciated, very practical, attracting a lot of attention from colleagues in the region and around the world.
Notably, the GENTIS report was in the Top 10 best poster reports voted by the ASPIRE Scientific Council. This is a great honor and a motivation to help the product development department of GENTIS continue to research, innovate, create, and offer valuable tests to Vietnamese citizens.
Besides, it is within the framework of scientific research cooperation between Hanoi Hospital of Andrology and Infertility and GENTIS Company, Specialist level 1 Doctor Nguyen Thanh Trung reported at the hall on "Clinical outcomes of mosaic embryo transfer patients". The results of the study show that for patients who do not have diploid embryos for embryo transfer, embryo transfer with mosaic results can be considered. The report attracted the attention of a large number of delegates participating in the conference because the research results brought a lot of impressive information about the rate of implantation, miscarriage, and survived pregnancy when evaluating the clinical outcomes after mosaic embryo transfer.
The research team reported "Clinical outcomes of patients with mosaic embryo transfer"
Moreover, GENTIS is also very honored when the company's Fertiscan test is applied in practice by Dinh Huu Viet, MSc.MD. - Hanoi Hospital of Andrology and Infertility to find out the cause of genetic infertility in men, contributing to improving the effectiveness of diagnosis as well as counseling. treatment for infertile couples at the Hospital. Even more amazing is the results of the Fertiscan test of GENTIS at Hanoi Hospital of Andrology and Infertility which was published by Dr. Viet in the report "Genetic analysis results in patient with non-obstructive azoospermia" at the ASPIRE conference. The report attracted the attention of a large number of delegates in the hall.
Dinh Huu Viet, MSc.MD. - Hanoi Hospital of Andrology and Infertility presented the report "Results of genetic analysis of infertility in patients with unknown causes"
ASPIRE 2024 is one of many international conferences that GENTIS regularly attends and reports to colleagues and friends from countries around the world. This shows that GENTIS is a prestigious, professional and developed unit not only in Vietnam but also internationally.
Hoang Thi Nhung, MSc. (representative of GENTIS) and a team of doctors at Hanoi Hospital of Andrology and Infertility participated in the 2024 ASPIRE Conference
In addition to the development and improvement of the quality of testing services, scientific research is also one of the spearheads that GENTIS pays special attention to, making development efforts to improve professional capacity as well as update knowledge and practical application to bring success to patients in the cycle of in vitro fertilization.
